Streetbeat News

Analyst Ratings

JAZZ

Analysts have mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), with recent evaluations showing a decrease in the average 12-month price target from $170 to $164.5. The company's financials reveal a strong net margin and ROA, but challenges in ROE and revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm

ARVN

Arvinas (NASDAQ:ARVN) has been analyzed by four analysts, showing a range of ratings from bullish to bearish. The average 12-month price target has decreased by 11.68% to $60.5. Analysts have maintained or lowered their ratings, reflecting a negative shift in sentiment. Despite a positive revenue growth rate of 40.37%, Arvinas faces challenges with net margin, ROE, and ROA below industry benchmarks.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) has been analyzed by five analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $38.8, a decrease from the previous $43.40. The company faces financial challenges, including a significant revenue decline and negative net margin, but has a strong ROE and ROA. Analysts maintain varied ratings, with some lowering their price targets.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm

DEI

Douglas Emmett (NYSE:DEI) received mixed analyst ratings, with a focus on neutral perspectives. Analysts have raised their 12-month price targets, indicating a positive outlook despite recent revenue declines. The company's financial metrics show strong profitability but high financial risk due to debt.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

SPRY

Analysts have provided mixed ratings for ARS Pharmaceuticals (NASDAQ:SPRY) over the past three months, with a recent average price target of $25.0. The company has shown significant revenue growth and maintains a strong financial position despite challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

FOX

FOXA

Seaport Research analyst David Joyce downgraded Fox Corp (NASDAQ:FOX) (NASDAQ:FOXA) from Buy to Neutral due to growth concerns despite a surge in political ad spending. The stock has exceeded the analyst's price target, reflecting political ad enthusiasm, but faces growth challenges.

Portfolio Pulse from Anusuya Lahiri

September 09, 2024 | 5:54 pm

JBLU

BofA Securities analyst Andrew G. Didora upgraded JetBlue Airways (NASDAQ:JBLU) from Underperform to Neutral, citing stable air travel demand and lower fuel costs. The price target was raised to $6, reflecting improved fundamentals and a favorable industry backdrop. Despite a challenged balance sheet, JetBlue's liquidity is expected to improve significantly by 2026, providing time for a turnaround. Recent positive revenue trends, especially in Latin America, and ongoing self-help measures support this outlook.

Portfolio Pulse from Anusuya Lahiri

September 09, 2024 | 5:39 pm

PTGX

Protagonist Therapeutics shares rose after Truist Securities initiated coverage with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:26 pm

RZLT

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Rezolute (NASDAQ:RZLT) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:25 pm

BCYC

Needham analyst Ami Fadia has reiterated a Buy rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $38.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:23 pm